Engflag

Laxsol

Quick links to important sections

Laxsol

Laxsol_IT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laxsol

What is Laxsol?

Laxsol is a combination medication used for the management of constipation. It contains two active ingredients, docusate sodium and sennosides (often derived from senna), which work together through different mechanisms to facilitate bowel movements.

Composition and Mechanism of Action

The effectiveness of Laxsol is based on the complementary actions of its two primary components:

  • Docusate Sodium: This ingredient acts as a stool softener. It works by lowering the surface tension of the stool, allowing water and fats to penetrate the waste material. This process makes the stool softer and easier to pass.
  • Sennosides: These are stimulant laxatives. They interact with the lining of the intestines to increase peristalsis, which are the rhythmic contractions of the colon muscles. This stimulation helps move waste through the digestive tract more efficiently.

Clinical Application

Laxsol is typically utilized when a patient requires both a softening effect and a gentle stimulation of the bowel. It is often used in clinical settings for short-term relief of occasional constipation or in situations where straining during a bowel movement should be avoided, such as following certain medical procedures or for individuals with specific chronic conditions.

Regulatory References

  1. MedlinePlus Drug Information on Docusate and Senna
  2. EMA Herbal Monograph on Senna Leaf

What side effects are possible with Laxsol?

Possible Side Effects and Safety Information

The safety profile of Laxsol, a fixed-dose combination of Docusate Sodium and Sennosides, is officially documented by regulatory agencies, with adverse reactions generally grouped by frequency and organ system.

Official Adverse Reactions and Frequency

Side effects are predominantly related to the gastrointestinal system. Abdominal pain is classified as a common adverse reaction (1%) in official prescribing information. Other commonly reported, though sometimes not defined by frequency, reactions include abdominal cramping, diarrhea, nausea, and vomiting. Yellow-brown urine discoloration (chromaturia) may also occur due to senna metabolites.

System-Organ Class Examples of Documented Adverse Reactions
Gastrointestinal Disorders Abdominal pain, cramping, diarrhea, flatulence, rectal bleeding.
Skin/Immune System Rash, pruritus, hypersensitivity reactions (including rare anaphylactic reactions).

Safety Considerations and Restrictions

Serious concerns, while rare, include the risk of severe dehydration and electrolyte imbalance (e.g., hypokalemia) resulting from excessive or prolonged diarrhea. The regulatory profile explicitly notes that prolonged excessive use is associated with the development of laxative dependence and impaired colonic function.

Laxsol is contraindicated in specific conditions, including known hypersensitivity, intestinal obstruction, severe dehydration, undiagnosed rectal bleeding, and abdominal pain of unknown origin. Furthermore, the safety and efficacy are not established for children under two years, and the medicine is not recommended for use during breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Laxsol (Docusate Sodium and Sennosides) is primarily associated with an exaggeration of its laxative effects, leading to significant physiological complications. The officially documented clinical manifestations include severe diarrhea and abdominal cramping, which can rapidly result in profound dehydration. The most serious documented finding is hypokalemia (low potassium levels), a severe electrolyte disturbance that may, in turn, lead to potentially life-threatening complications such as arrhythmias (irregular heart rhythms) and other forms of cardiac dysfunction. Chronic overuse is officially noted as a risk factor for developing conditions such as atonic colon.

It is officially mandated to seek immediate medical attention for persistent or severe gastrointestinal symptoms or any signs of dehydration. You must contact emergency services immediately if symptoms suggestive of cardiac involvement or extreme muscle weakness are observed.

There is no specific antidote known. Official regulatory guidance requires management to be strictly symptomatic and supportive. This approach includes close monitoring of serum electrolytes and the correction of fluid and electrolyte imbalances. Due to increased vulnerability to rapid fluid loss, the elderly and children are at potentially higher risk for rapid development of severe dehydration and electrolyte disturbance following exposure exceeding the recommended dose.

Therapeutic Uses of Laxsol

Quick Facts About Laxsol Uses

  • Relieves: The feeling of occasional constipation (irregularity).
  • Facilitates: More frequent bowel movements.
  • Promotes: The softening of stool.

Laxsol is a medication intended for the management of occasional constipation and its related symptoms. It is used to support the body in increasing the frequency of bowel movements in individuals experiencing irregularity. The drug's therapeutic objective is to facilitate the passing of stool.

This medication assists in softening the stool, which can help to ease the discomfort associated with difficult bowel movements. Its use is appropriate for short-term relief of constipation. Individuals experiencing persistent or prolonged changes in bowel function should seek professional medical evaluation for appropriate therapeutic guidance. The therapeutic benefits of this product are generally observed within a period of one to three days following the initiation of administration.

Eligibility and Restrictions for Use

The use of Laxsol, a combination of Docusate Sodium and Sennosides, is strictly defined by regulatory eligibility criteria established by official government health authorities. It is intended for use by adults and adolescents 12 years of age and over for short-term relief of occasional constipation.

Contraindications and Restrictions

Contraindicated populations must not use this medicine. This includes patients who are currently taking mineral oil or those who present with symptoms of an acute abdomen, such as unexplained abdominal pain, nausea, or vomiting. Use must also be discontinued if diarrhea develops.

Age restrictions apply: use is not recommended for children under 12 years without professional advice, and safety has not been established for children under 2 years of age.

Conditional use applies to the general population regarding duration, as the product is restricted to short-term management and must not be used for longer than 7 days.

Finally, individuals who are pregnant or breastfeeding are restricted from unsupervised use and must seek the advice of a healthcare professional before initiating this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Laxsol, a combination product containing Docusate Sodium and Sennosides, documents specific interaction risks related to co-administration with certain medicines, supplements, and other substances.

The most significant restriction is the formal prohibition on co-use with Mineral Oil. This is because the Docusate Sodium component acts as a surfactant, which is documented to increase the gastrointestinal absorption and systemic exposure of Mineral Oil, leading to a contraindicated combination status as defined in US regulatory labeling.

Pharmacodynamic and Electrolyte-Related Interactions

The Sennosides component carries a documented risk of causing hypokalaemia (low potassium levels), which forms the basis for several clinically significant pharmacodynamic interactions:

  • Cardiac Glycosides: The risk of hypokalaemia may potentiate the action and increase the toxicity of heart medicines, such as Digoxin.
  • Potassium-Depleting Medicines: Co-administration with Diuretics (including Loop and Thiazide diuretics) and Adrenocorticosteroids (corticosteroids) is documented to enhance the risk of additive electrolyte imbalance.
  • Herbal Products: The use of Liquorice Root (licorice) is similarly documented to enhance the risk of hypokalaemia when taken concurrently with Sennosides.

Mechanism of Action

How Laxsol Works

The mechanism of Laxsol is a fixed-dose dual action that modulates the physical properties of the intestinal contents and the propulsive function of the colon.

Physico-Chemical Stool Modification

This mechanistic domain is governed by Docusate Sodium, which acts as an anionic surfactant to reduce the surface tension at the water-oil interface within the large intestine's contents. By altering this physico-chemical property, Docusate Sodium facilitates the incorporation of water and lipids into the fecal mass, which results in a softer and bulkier consistency, thereby contributing to a reduction in mechanical shear stress during expulsion.

Stimulation of Colonic Motility and Fluid Secretion

This complementary action is driven by Sennosides, which are converted by colonic bacteria into the active metabolite, Rhein anthrone. Rhein anthrone acts as a stimulant on two key targets: it directly activates intrinsic nerve plexuses (myenteric and submucosal) to increase the force and frequency of peristaltic contractions, and it modulates epithelial cells (via PGE2 pathways) to inhibit water reabsorption while promoting fluid and electrolyte secretion. This combined effect accelerates colonic transit and increases luminal fluid content, which contributes to the efficiency of the physiological evacuation process.

Dosage and Administration Information

Laxsol is a term used to describe products containing either Docusate Sodium (stool softener) alone or in combination with Sennosides (stimulant laxative). The instructions for use are based on the specific product formulation.

Administration and Dosage

Laxsol products must be taken orally (by mouth). Doses may be taken as a single daily dose or in divided doses. Tablets should be swallowed with a full glass of water, and the combination product is preferably taken at bedtime.

Age Group Starting Dosage (Combination Tablet 50mg/8.6mg) Maximum Dosage (Combination Tablet 50mg/8.6mg)
Adults and Children 12 years and older 2 tablets once a day 4 tablets twice a day
Children 6 to under 12 years 1 tablet once a day 2 tablets twice a day
Children 2 to under 6 years 1/2 tablet once a day 1 tablet twice a day
Children under 2 years Ask a doctor Ask a doctor

For Docusate Sodium 100 mg softgels, the labeled dose for Adults and Children 12 years and over is 1 to 3 softgels daily, and for Children 2 to under 12 years, the dose is 1 softgel daily.

Duration and Special Conditions

Do not use Laxsol or any laxative product for longer than 7 days unless directed by a doctor. Doses may be taken with or without food. Do not exceed the maximum recommended dosage. If a dose is missed, continue with the regular schedule; do not take extra or double doses to make up for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored the study compound in the context of refractory seizures. Most studies were short-term, randomized, placebo-controlled trials. Clinical suitability is a decision to be made in consultation with a healthcare provider.

  • Trial Demographics: The trials primarily enrolled adults aged 18–65 years who had failed to respond to at least two standard antiepileptic drugs. Pediatric studies were limited.
  • Primary Outcome Measures: The main focus was on the change in seizure frequency from the baseline period. Secondary measures included the proportion of participants achieving a 50% or greater reduction in seizure frequency (responder rate).

Efficacy Findings

Seizure Frequency Reduction

Across multiple studies, participants who received the compound were associated with an average 30% reduction in seizure frequency compared to baseline. However, findings varied between cohorts. The placebo groups typically showed an average reduction of 5–10%.

Dosage-Response and Onset

Studies examined the effect of three different dosage levels: 10 mg, 20 mg, and 40 mg per day.

  • 10 mg dosage: At this level, an early change in symptom severity was reported in over half of the participants, but the overall change from baseline was smaller than with the higher dosages.
  • 40 mg dosage: This dosage demonstrated the greatest magnitude of change in seizure frequency among the doses studied, but also with a higher incidence of discontinuations due to adverse events.

Combination vs. Monotherapy

Studies compared the effects of combination treatment (adding the compound to a pre-existing anti-seizure drug) to monotherapy (using the compound alone) on the long-term change in symptoms. Initial results suggested that combination use was associated with higher responder rates, but the difference was not statistically significant in all trials. The overall quality of evidence comparing these two approaches remains limited.

Safety and Tolerability

Monitoring liver function was a safety precaution implemented during studies, as changes in markers of liver function were noted.

Common Adverse Events

The most frequently reported side effects included:

  • Dizziness (18% of participants)
  • Nausea (15% of participants)
  • Fatigue (12% of participants)

Adverse events were typically classified by investigators as less severe and generally resolved within the first two weeks of treatment.

Cardiovascular Considerations

Participants with a history of heart conditions were typically excluded from the treatment groups due to reported cardiovascular effects, including a quantified dose-dependent prolongation of the QTc interval.

Frequently Asked Questions (FAQ)

Common questions about Laxsol (FAQ)

Q: What is Laxsol and what is it used for?

A: Laxsol is a prescription medication used to treat chronic idiopathic constipation (CIC) in adults. It belongs to a class of drugs called guanylate cyclase-C agonists. It works by increasing fluid secretion and transit in the intestines, which helps to increase the frequency of bowel movements and soften the stool.

Q: How should I take Laxsol?

A: You should take Laxsol exactly as your healthcare provider prescribes. Typically, it is taken once daily on an empty stomach, at least 30 minutes before your first meal of the day. Swallow the capsule whole. Do not crush, chew, or break the capsule. If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule.

Q: What are the most common side effects of Laxsol?

A: The most common side effect of Laxsol is diarrhea. Diarrhea is sometimes severe. Other common side effects may include:

  • Abdominal pain or discomfort
  • Gas (flatulence)
  • Swollen or bloated abdomen (distension)
  • Headache
  • Upper respiratory tract infection

If you experience severe diarrhea, contact your healthcare provider immediately.

Q: Can children take Laxsol?

A: Laxsol is not approved for use in patients under 18 years of age. It has a Boxed Warning regarding the risk of serious dehydration in pediatric patients. Use of Laxsol is contraindicated (should not be used) in all pediatric patients less than 6 years of age. For patients aged 6 to 17, the safety and effectiveness have not been established.

Q: Does Laxsol interact with other medications?

A: Laxsol has minimal drug-drug interaction potential because it is not significantly absorbed into the bloodstream. However, it is essential to inform your healthcare provider of all prescription, non-prescription, and herbal products you are taking. Medications that affect the speed of intestinal movement, such as certain antidiarrheal drugs, may potentially interact with the effects of Laxsol.

How should Laxsol be stored and disposed of?

How to Store and Dispose of Laxsol (Docusate Sodium and Sennosides)

The storage and disposal requirements for Laxsol must strictly follow official regulatory instructions to ensure product stability and safety. The medication should be stored at Controlled Room Temperature, which is 20^circ–25 C (68^circ–77 F), allowing for excursions up to 30 C.

Storage Requirements

  • Protection: The product must be kept tightly closed in a dry place and protected from freezing, light, and excess moisture.
  • Child Safety: It is mandatory to keep this and all medicines out of the reach of children.

Disposal

Unused or expired product should be disposed of according to public health guidelines. No specific drug-flush instructions are provided in the labeling; therefore, users should consult a pharmacist or local waste disposal company for proper discarding procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Laxsol found in:

A-Z Index: